+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oncology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 185 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5970520
Free Webex Call
10% Free customization

Targeted Drugs is the fastest growing segment, North America is the largest regional market

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global Oncology Drugs Market, valued at USD 228.65 Billion in 2024, is projected to experience a CAGR of 13.33% to reach USD 484.54 Billion by 2030. Oncology drugs are pharmaceutical agents developed for the prevention, diagnosis, and treatment of cancer, encompassing a diverse range of therapeutic modalities including chemotherapy, targeted therapies, and immunotherapies. The market's growth is primarily supported by the increasing global incidence of cancer, the demographic shift towards an aging population, and continuous advancements in biotechnological research and development driving the discovery of novel treatments.

Key Market Drivers

The global oncology drugs market is significantly influenced by the increasing global cancer incidence. The rising prevalence of cancer worldwide, fueled by aging populations, lifestyle changes, and environmental factors, creates a substantial and continuously growing patient pool requiring advanced therapeutic interventions. This demographic shift directly translates into heightened demand for effective cancer treatments, necessitating a broader portfolio of pharmaceutical solutions. According to the World Health Organization and the International Agency for Research on Cancer, in their February 2024 report, an estimated 20 million new cancer cases occurred globally in 2022, underscoring the urgent and expanding need for oncology drugs.

Key Market Challenges

The extensive expenditure associated with oncology drug development and stringent regulatory approval processes presents a significant impediment to the growth of the Global Oncology Drugs Market. The substantial financial investment required for research, preclinical studies, and multiple phases of clinical trials, coupled with the high failure rate of experimental therapies, makes the development pathway costly and uncertain. This financial burden restricts the number of new treatments that can be brought to market, as companies must carefully prioritize projects with the highest likelihood of success and return on investment.

Key Market Trends

The rising integration of artificial intelligence in drug development profoundly reshapes the global oncology market by accelerating the discovery and development of novel therapies. AI algorithms streamline target identification, optimize lead compounds, and predict clinical outcomes, significantly reducing the timelines and costs associated with bringing new cancer treatments to market.

This technological shift enhances research and development productivity. In April 2025, Tempus AI, Inc. announced strategic collaborations with AstraZeneca and Pathos AI, Inc. to build a multimodal foundation model in oncology, involving $200 million in data licensing and model development fees, highlighting investment in AI driven therapeutic advancements. According to the Pistoia Alliance's 2024 Lab of the Future report, AI was a top investment area for 62 percent of respondents over the next two years.

Key Market Players Profiled:

  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Astrazeneca Plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Johnson & Johnson

Report Scope:

In this report, the Global Oncology Drugs Market has been segmented into the following categories:

By Drug Class:

  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Drugs Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncology Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others)
5.2.2. By Route of Administration (Oral, Parenteral, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Oncology Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Oncology Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Oncology Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Oncology Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Oncology Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Oncology Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Oncology Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Oncology Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Oncology Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Oncology Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Oncology Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Oncology Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Oncology Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Oncology Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Oncology Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Oncology Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Oncology Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Oncology Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Oncology Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Oncology Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. South America Oncology Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Oncology Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Oncology Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Oncology Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Oncology Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Astellas Pharma Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer, Inc.
15.3. Novartis AG
15.4. Astrazeneca Plc
15.5. Merck & Co., Inc.
15.6. F. Hoffmann-La Roche Ltd.
15.7. Amgen, Inc.
15.8. Bristol-Myers Squibb Company
15.9. Abbvie Inc.
15.10. Johnson & Johnson
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this Oncology Drugs market report include:
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Astrazeneca Plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Abbvie Inc.
  • Johnson & Johnson

Table Information